Compare Kroger Co (KR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs State Street SPDR S&P Biotech ETF — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Kroger Co is far larger — about 3.6× State Street SPDR S&P Biotech ETF's market cap, and Kroger Co pays a 2.54% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KR | XBI | |
|---|---|---|
Market Cap | $36.27B | $10.11B |
Volume | 8,301,523 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $75.60 | $169.55 |
52-Week Low | $55.53 | $104.99 |
Typical Hold Time | 108 Days | 38 Days |
Enterprise Value | $57.69B | — |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with $147.12B revenue, 23.11% gross margins, and consistent dividend payments. Recent earnings beat expectations in Q2 2026, while Q1 2026 slightly missed. Technical indicators show the stock trading near pivot point resistance at $62 with solid support at $59-60 levels. The company maintains robust cash flow generation with $5.79B from operations in 2025.
Kroger presents a compelling investment case with attractive valuation (P/S 0.26), strong analyst support (47.72% buy ratings), and $70.62 consensus price target offering 15% upside. Key risks include integration challenges with Giant Eagle acquisition, cost pressures affecting 2026 margins, and competitive threats from Walmart. The stock's digital growth initiatives and retail media expansion provide growth catalysts, though investors should monitor identical sales performance and acquisition integration progress.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
